Site One Therapeutics, Inc. announced it raised $14.9 Million in an initial filing from an offering of $15.1 Million

Company

Location

About

SiteOne Therapeutics, Inc. is a biopharmaceutical company developing selective ion channel modulators aimed at treating conditions such as pain and cough. The company's focus is on creating non-opioid treatments that target sensory hyperexcitability disorders. Their lead program targets the NaV1.8 channel, with a focus on providing effective analgesia while minimizing side effects and abuse potential. SiteOne's innovative approach prioritizes the development of therapeutics that directly affect the peripheral nervous system.